Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Doxorubicin Stories

2011-04-21 07:00:00

SAN FRANCISCO, April 21, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company's oncology drug candidate, NKTR-102, has been granted orphan drug status for the treatment of women with ovarian cancer by the U.S. Food and Drug Administration (FDA). "This designation is an important step in the overall development program for NKTR-102 and underscores our commitment to treating women with ovarian cancer," said Dr. Lorianne Masuoka, Senior Vice President and...

2011-04-20 03:33:00

BARCELONA, April 20, 2011 /PRNewswire/ -- - Advancell has announced the initiation of a clinical phase IIb study of its treatment ATH008 for palmar-plantar erythrodysesthesia syndrome, or hand-foot syndrome, a painful side effect of chemotherapy. This treatment could be available on the market by the end of 2015 or beginning of 2016 - Hand-foot syndrome is a cutaneous reaction involving redness, peeling, blisters and intense pain on the palms of hands or the soles of feet. This...

2011-04-04 00:30:00

SEATTLE, April 4, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that the April 2011 edition of the peer reviewed journal, Leukemia & Lymphoma (April 2011; 52(4): 620-628) published results of a phase I/II clinical trial evaluating the effect of cyclophosphamide, pixantrone, vincristine, and prednisone ("CPOP") in treating patients with aggressive non-Hodgkin's lymphoma ("NHL") who relapsed following initial therapy with cyclophosphamide,...

2011-04-02 00:00:28

MM-111 in pre-clinical combinations with lapatinib and endocrine therapies MM-302 in pre-clinical studies explaining its mechanism of action Cambridge, Mass. (Vocus/PRWEB) April 01, 2011 Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-111 and MM-302, two candidates from the company's novel pipeline of five cancer therapeutics, at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) being held April 2 "“ 6, 2011,...

2011-03-21 01:30:00

SEATTLE, March 21, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL"). The clinical trial is now open to patient enrollment. The trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed...

2011-03-16 08:32:00

MONTREAL, March 16 /PRNewswire/ - Soon, drug delivery that precisely targets cancerous cells without exposing the healthy surrounding tissue to the medication's toxic effects will no longer be an oncologist's dream but a medical reality, thanks to the work of Professor Sylvain Martel, Director of the Nanorobotics Laboratory at Polytechnique Montr©al. Known for being the world's first researcher to have guided a magnetic sphere through a living artery, Professor Martel is...

2011-03-16 06:45:00

SYRACUSE, N.Y., March 16, 2011 /PRNewswire/ -- Scientists in Syracuse University's Chemistry Department have created a new drug delivery system expected to advance the effectiveness of cancer-killing drugs. It uses gold nanoparticles with attached DNA that binds to a proven anti-cancer drug, Doxorubicin or DOX. Preliminary tests indicate this delivery device has the potential to significantly improve the results of cancer chemotherapy. DOX is currently used against cancers of the breast,...

2011-03-10 00:30:00

SEATTLE, March 10, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced the final clinical trial design of a randomized pivotal trial of pixantrone for the treatment of diffuse large B-cell lymphoma ("DLBCL") following discussions with the U.S. Food and Drug Administration's (the "FDA") Division of Hematologic Products (the "DHP") . The new clinical trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus...

2011-03-09 18:24:10

Nanodiamond-drug combo significantly improves treatment of chemotherapy-resistant cancers Chemotherapy drug resistance contributes to treatment failure in more than 90 percent of metastatic cancers. Overcoming this hurdle would significantly improve cancer survival rates. Dean Ho, an associate professor of biomedical engineering and mechanical engineering at Northwestern University, believes a tiny carbon particle called a nanodiamond may offer an effective drug delivery solution for...

2011-03-03 00:30:00

SEATTLE, March 3, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has met with officials of the FDA's Office of New Drugs ("OND") in Maryland and presented its arguments supporting the Company's belief that the data contained in its New Drug Application ("NDA") 22-481 support the conclusion that pixantrone is effective for its planned use. "We appreciate OND's consideration of our appeal. While we understand disputes of this type are a...